Back to FARALLON CAPITAL MANAGEMENT, L.L.C.

CRNX
Showing 8 of 11 quarters

Position history for FARALLON CAPITAL MANAGEMENT, L.L.C.'s holdings in CRINETICS PHARMACEUTICALS IN

FARALLON CAPITAL MANAGEMENT, L.L.C. holds 8.3M shares of CRNX (CRINETICS PHARMACEUTICALS IN), worth $302.8M as of 2026-Q1. The position was increased (+20.3% shares). CRNX represents 1.7% of FARALLON CAPITAL MANAGEMENT, L.L.C.'s portfolio.

Current Value

$302.8M

Current Shares

8.3M

Total Value Change

+$280.6M

Total Shares Change

+7.8M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q1
Latest
Increased
8.3M
+20.3%
$302.8M1.7%$40.12
58
2025-Q4
Increased
6.9M
+20.2%
$322.7M1.5%$47.39
58
2025-Q3
Increased
5.8M
+24.2%
$240.3M1.0%$43.51
53
2025-Q2
Increased
4.6M
+0.9%
$133.6M0.6%$29.96
43
2025-Q1
Increased
4.6M
+13.0%
$154.5M0.9%$34.73
48
2024-Q4
Increased
4.1M
+250.7%
$208.4M1.1%$50.67
78
2024-Q3
Increased
1.2M
+133.8%
$59.4M0.3%$50.75
57
2024-Q2
Increased
497,000
+9840.0%
$22.3M0.1%$44.79
55

Other major holders of CRNX: FMR LLC, VANGUARD GROUP INC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used